BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies ...
Praxis Precision Medicines (NASDAQ:PRAX) announced Friday that the company will advance its Essential3 program for its lead asset ulixacaltamide against the neurological disorder essential tremor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback